- Medicon Valley
- News & Events
- News
- Events
- Medicon Valley Newsletter
- August 2008
- June 2008
- May 2008
- April 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- November 2005
- October 2005
- September 2005
- Business Opportunities
- Science & Research
- Networks
- Services & Support
- Companies & Institutions
- At Your Service
Medicon Valley Biomedical Newsletter
The Medicon Valley Biomedical Newsletter is intended for decision makers in pharmaceutical and biotech companies, investors and other professionals who wish to keep updated on business related activities in the Medicon Valley.
June
-
Alligator Bioscience and PolyTherics Announce Strategic Collaboration
19 Jun 2008
Alligator Bioscience AB and PolyTherics Ltd have announced the establishment of a new alliance. Under the terms of the collaboration agreement, PolyTherics and Alligator will explore the biological ef...
-
Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
27 May 2008
Bavarian Nordic A/S has initiated Phase I/II clinical study with its HIV vaccine candidate: MVA-BN HIV multiantigen. The MVA-BN HIV multiantigen vaccine encodes eight genes from HIV, including Nef and...
-
BioInvent and ThromboGenics Announce Strategic Alliance with Roche
19 Jun 2008
BioInvent International AB and ThromboGenics NV has announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclo...
-
BRIC Identifies Mechanism for microRNA Involvement in Cancer
29 May 2008
Researchers at the Biotech Research & Innovation Centre, BRIC, have identified a novel mechanism for microRNA regulation of protein synthesis and involvement in cancer. The results are published i...
-
Santaris Pharma Enters Phase I Clinical Trial
29 May 2008
Santaris Pharma A/S has commenced a Phase I human volunteer trial of the world's first microRNA medicine to be tested in man, SPC3649, LNA-antimiRTM-122. The study is being conducted by PhaseOneTr...
-
Symphogen Enters Into Strategic Collaboration with Genentech
11 Jun 2008
Symphogen A/S has announced that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets. In thi...
{9825AE24-85C6-4D55-B120-AA0977562CDC}.pdf
Medicon Valley Biomedical Newsletter is published by
Region Skåne and Copenhagen Capacity.
We assist foreign companies in finding locations and partnerships in Medicon Valley. We offer free assistance at each step of the business development phase. Visit www.mediconvalley.com or contact us to learn more about the opportunities that await your company in Medicon Valley.
|
Copenhagen Capacity |
Region Skåne |
If you have any comments on the Medicon Valley Biomedical Newsletter please contact the editor at info@mediconvalley.com.
Here you can subscribe to the Medicon Valley Academy Newsletter
The MVA newsletter is an e-mail news service for Medicon Valley Academy (MVA) members and other actors within life science. The newsletter brings you information on new MVA initiatives and activities, editorials on issues of topical interest, news from the region together with available jobs and relevant life science events.
Click here to subscribe or visit www.mva.org.